Rejection and tacrolimus conversion therapy in paediatric liver transplantation.
Rejection and efficacy of rescue therapy with tacrolimus were evaluated in 50 children who underwent primary, ABO-compatible, liver transplantation. Six patients who died within the first week and one child who underwent retransplantation from an ABO-incompatible donor were excluded from the study. No patient or graft were lost due to rejection. We observed 48 episodes of rejection in 33 patients. Fourteen patients required conversion to tacrolimus for steroid-resistant rejection with resolution of rejection. One of these children developed PTLD. Other indications for conversion were neurotoxicity and hirsutism. One patient developed blindness of unknown origin after the conversion. Other side effects of tacrolimus were minor and resolved by lowering the dose. Five patients developed rejection after conversion; all achieved resolution with either steroid therapy or increase of tacrolimus dose. In conclusion, our study confirms that tacrolimus is an effective rescue therapy for paediatric liver transplantation.
Spada
M
M
Liver Transplantation Center and, Ospedali Riuniti di Bergamo, Italy. mspada@ospedaliriuniti.bergamo.it
Corno
V
V
Colledan
M
M
Segalin
A
A
Lucianetti
A
A
Torre
G
G
Riva
S
S
Sonzogni
A
A
Petz
W
W
Gridelli
B
B
D000017:ABO Blood-Group System; D001787:Blood Group Incompatibility; D002648:Child; D016572:Cyclosporine / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000517:prevention & control*; D006085:Graft Survival; D006628:Hirsutism / Q000139:chemically induced; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D007223:Infant; D016031:Liver Transplantation / Q000276:immunology* / Q000401:mortality / Q000502:physiology; D018579:Patient Selection; D011241:Prednisone / Q000627:therapeutic use; D015996:Survival Rate; D016559:Tacrolimus / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D013997:Time Factors
D000017:ABO Blood-Group System; D007166:Immunosuppressive Agents; D016572:Cyclosporine; D011241:Prednisone; D016559:Tacrolimus